AI Science Tracker

Longitudinal EHR machine learning identifies patients who may need autoimmune rheumatic-disease evaluation years earlier

Icahn School of Medicine at Mount Sinai; University of Maryland School of Medicine; Hospital for Special Surgery · 25 Apr 2023 · medicine

Discovery

Longitudinal EHR machine learning identifies patients who may need autoimmune rheumatic-disease evaluation years earlier

A random-forest model trained on longitudinal electronic health records from 161,584 people across two institutions identified records associated with high-specificity autoantibody testing for systemic autoimmune rheumatic diseases (SARDs). The model achieved AUROC 0.93 in internal validation and 0.87 on the external All of Us cohort. In a separate BioMe cohort, model probabilities tracked SARD and other autoimmune diagnoses; records could predict later autoantibody testing and rheumatology encounters up to five years before those events. The study also found higher autoantibody yield among model-prioritized individuals than under the comparison clinical-testing rate.

Technology: Random-forest machine-learning model using longitudinal electronic-health-record diagnoses, medications, laboratory results and vital signs

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: A random-forest model trained on longitudinal electronic health records from 161,584 people across two institutions identified records associated with high-specificity autoantibody testing for systemic autoimmune rheumatic diseases (SARDs).
  • Still unknown: The model predicts clinical suspicion and need for rheumatological testing, not a SARD diagnosis. The study was retrospective and opportunistic; autoantibody testing and rheumatology encounters are imperfect proxies for clinical need, and some diseases were not included in the training target. The authors state prospective studies are needed to determine whether model-guided testing improves care or outcomes. The five-year lead is retrospective prediction of later evaluation events, not proven earlier diagnosis or patient benefit.
  • AI role: The model ranked patients by probability of receiving SARD-specific autoantibody testing, using clinical data preceding the test or rheumatology encounter. Investigators evaluated performance in internal validation, the external All of Us cohort and an independent BioMe cohort, and tested whether higher scores tracked diagnosed autoimmune disease and identified later testing or encounters earlier in retrospective records.

Evidence sources: https://www.nature.com/articles/s41467-023-37996-7.pdf

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 40 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.